uniQure N.V. (NASDAQ: QURE) Surges on Cantor Fitzgerald Upgrade and BLA Filing Plans

• uniQure N.V. (NASDAQ: QURE) received an "Overweight" rating upgrade from investment firm Cantor Fitzgerald, driven by its planned Biologics License Application (BLA) for its lead gene therapy candidate, AMT-130.
• The U.S. Food and Drug Administration (FDA) has indicated that mid-stage study data for AMT-130, a potential Huntington's disease treatment, could support accelerated approval, with uniQure aiming for a Q3 2026 BLA submission.
• Following the news, uniQure's stock price surged by 77.43%, reaching $47.89, and its market capitalization climbed to approximately $3.02 billion, reflecting strong investor interest and high trading volume.

uniQure N.V. (NASDAQ: QURE) is a Dutch drugmaker specializing in the development of innovative gene therapies. These advanced treatments are designed to address diseases by targeting their genetic roots. The company is currently focused on its lead candidate, AMT-130, a potential one-time treatment for Huntington's disease, a severe neurodegenerative disorder.

On June 17, 2026, investment firm Cantor Fitzgerald upgraded its rating for uniQure N.V. from Neutral to Overweight. This positive change in outlook was driven by the company's strategic plan to file a Biologics License Application (BLA). A BLA is a formal request to the FDA to market a new biological product, signifying a major step towards commercialization.

The filing plan for AMT-130 comes after the U.S. Food and Drug Administration (FDA) agreed that data from a mid-stage study could support an accelerated approval, as highlighted by Reuters. This expedited process can significantly speed up the availability of crucial drugs for serious conditions. uniQure intends to submit the BLA in Q3 2026, marking a key milestone in its drug development pipeline.

Following this significant news, uniQure's stock price was $47.89 at the time of the rating change. This represented a substantial single-day increase of $20.90, or 77.43%. The stock's daily trading fluctuated between a low of $42.50 and a high of $48.74, clearly showing strong investor interest and market confidence in the company's prospects.

This surge in activity pushed uniQure's market capitalization to approximately $3.02 billion. Market capitalization is the total dollar value of a company's outstanding shares, reflecting its overall valuation. Trading volume was exceptionally high at around 1.92 million shares, well above its usual average, indicating a significant surge in investor activity and demand for uniQure stock.